Result of Potassium-Competitive Acid Blockers in the Treatment of Severe Gastroesophageal Reflux Disease-Associated Esophageal Ulcer
Abstract
Esophageal ulcers are rare but can become severe and require prompt treatment. Gastroesophageal reflux disease (GERD), one of the causes, is a frequently encountered disease that considerably affects the daily lives of patients; therefore, appropriate management is required. Acid-suppressive therapy is the mainstay of treatment. Here, we report a case in which potassium-competitive acid blocker (P-CAB) therapy was associated with ulcer healing and symptom improvement caused by GERD. An 81-year-old woman was referred for further evaluation after abnormal gastric imaging findings were detected during a routine health checkup. The patient had no remarkable medical history or comorbidities. Upper gastrointestinal endoscopy revealed an esophageal ulcer caused by severe GERD. Acid-suppressive therapy with P-CABs was effective, resulting in the rapid resolution of the ulcer and improvement of reflux-like symptoms. The dose was subsequently reduced as maintenance therapy, and the patient continued to do well without symptom recurrence. As illustrated in the present case, GERD has the potential to progress to esophageal ulceration; therefore, prompt initiation of treatment is necessary. P-CABs may be a useful therapeutic option in similar cases.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use
- Ivth brazilian consensus conference on helicobacter pylori infection
- A pSMAD/CDX2 complex is essential for the intestinalization of epithelial metaplasia
- S2k-Leitlinie Gastroösophageale Refluxkrankheit und eosinophile Ösophagitis der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – März 2023 – AWMF-Registernummer: 021–013
- Step-by-step management of refractory gastresophageal reflux disease
- Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger–Ellison Syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.